Overview of Дип Рилиф

Quick Facts

Property	Description
Active Ingredients	Ibuprofen, Levomenthol
Form	Topical Gel
Pharmacological Class	NSAID + Counterirritant
General Purpose	Localized relief of pain and inflammation
Type	Combination Drug

What is Дип Рилиф?

1. What Type of Medicine is Дип Рилиф and What is its Purpose?

Дип Рилиф (Deep Relief) is an Over-the-Counter (OTC) topical pharmaceutical product that functions as a combined analgesic and anti-inflammatory agent. Its core purpose is to provide highly localized comfort and reduce inflammation in muscles and joints, often used for issues like minor sprains or strains. As a topical gel, the medicine is strictly for external application, ensuring a local, targeted approach to discomfort, a strategy often utilized in managing acute musculoskeletal pain.

This dual-action preparation allows it to be more versatile than single-ingredient rubs. It is intended to offer comprehensive relief by combining a well-known anti-inflammatory with a fast-acting surface sensation.

2. Composition: What Active Ingredients Make Up Дип Рилиф?

The gel contains two distinct active ingredients: Ibuprofen and Levomenthol. Ibuprofen, the primary therapeutic agent, is a synthetic compound and a recognized member of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. It is the component responsible for deep-acting anti-inflammatory relief.

The second component, Levomenthol, acts as a Counterirritant. This ingredient is crucial for providing a rapid, perceptible effect. The specific combination of Ibuprofen and Levomenthol is recognized for its use in treating minor external trauma. Both agents are mixed into a smooth, non-greasy aqueous gel base for effective skin penetration.

3. How Do the Active Ingredients Work Together for Relief?

The active ingredients work in tandem to deliver simultaneous anti-inflammatory action and immediate cooling relief. Ibuprofen works at a deeper tissue level by reducing the chemical mediators that cause swelling and stiffness, promoting recovery. Levomenthol, in contrast, provides a rapid surface cooling sensation, which creates a distraction from pain, complementing the deeper action of the NSAID.

What side effects are possible with Дип Рилиф?

Possible Side Effects and Safety Information

The safety profile of this topical gel, which contains ibuprofen and levomenthol, is primarily characterized by effects localized to the site of application. Regulatory documents classify adverse reactions according to the organ system affected and their reported frequency.

Frequency and System-Organ Classifications

The most common adverse reactions listed in official labeling are related to Skin and Subcutaneous Tissue Disorders. These are often classified as Common and include localized reactions such as dermatitis (including contact dermatitis), skin rash, pruritus (itching), and erythema (redness).

Due to the low systemic absorption of the topical NSAID, reactions affecting other systems are rare or of unknown frequency. These systemic effects, which are possible with high exposure, involve the Gastrointestinal Disorders (e.g., abdominal pain, dyspepsia) and Renal and Urinary Disorders (e.g., renal impairment).

Serious Adverse Reactions and Safety Constraints

While Very Rare, the label documents serious potential risks. These include generalized Hypersensitivity reactions, such as anaphylaxis, and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS).

The safety profile includes restrictions tied to exposure. Systemic undesirable effects are noted as being more likely if the gel is applied over large areas of skin, under occlusive dressings, or for a prolonged duration. Regulatory documents advise that effects may be reduced by limiting use to the shortest possible duration.

Population-Specific Safety: The gel is Contraindicated for use during the last trimester of pregnancy, and its use is not recommended in children under 12 years of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile indicates that overdosage is unlikely to occur with the correct topical application of the gel. The primary overdose risk is associated with the accidental ingestion of the product, which could lead to systemic exposure of the active ingredient, Ibuprofen.

Documented Overdose Manifestations and Action

Feature	Official Regulatory Statement
Documented Symptoms	Systemic exposure may present with headache, vomiting, drowsiness, nausea, diarrhoea, epigastric pain, and tinnitus.
Serious Outcomes	Documented serious systemic effects include hypotension (low blood pressure) and gastrointestinal bleeding.
Mandated Emergency Action	If the gel is accidentally swallowed, immediately contact a doctor or nearest casualty department/hospital.

If the gel is swallowed, the immediate action mandated by regulatory authorities is to seek professional medical attention. The treatment approach for systemic overdose is generally defined as symptomatic and supportive, and specific procedural steps include the consideration of correcting severe electrolyte abnormalities. No specific antidote is known or listed in official documentation.

Population-specific considerations exist, as sufficient systemic exposure during the third trimester of pregnancy carries risks, including inhibition of spontaneous labour and increased bleeding complications.

Therapeutic Uses of Дип Рилиф

What Дип Рилиф treats: main uses and benefits

The topical formulation is applied in situations involving certain distressing symptoms linked to the musculoskeletal system. This combination of active agents may be part of symptomatic management for soft-tissue injuries, sprains, and muscle strains. The product is relevant in areas where short-term symptom management is appropriate for symptoms related to inflammatory or irritative states and physical discomfort.

Therapeutic Scope and Support

The gel is commonly used to help with easing localized, acute aches, as well as chronic stiffness typical of non-serious or episodic rheumatic and arthritic discomfort. This approach helps address symptom clusters that may become intense or disruptive, such as the pain and swelling accompanying a sprain. This medication contributes to easing the overall symptom load and supports general well-being during symptomatic phases. It is applicable within conditions involving episodic or fluctuating manifestations, and assists with maintaining functional stability.

Quick Fact: Relief for Localized Musculoskeletal Discomfort
Target Symptoms	Acute aches, pain, tenderness, and associated swelling.
Typical Contexts	Minor sports injuries, muscle strains, and non-serious rheumatic aches.
Primary Benefit	Provides targeted symptomatic support to ease symptom load.

Eligibility and Restrictions for Use

Official Eligibility Rules for Дип Рилиф

Regulatory documentation strictly defines which populations are eligible to use this topical gel, based on age, physiological status, and underlying health conditions. Eligibility criteria may vary slightly by region; the following rules are based on official government labeling.

Who Must Not Use (Contraindications)

Population/Condition	Regulatory Status
Known hypersensitivity to Ibuprofen, Levomenthol, aspirin, or any other NSAID.	Contraindicated
Individuals with asthma, rhinitis, or urticaria precipitated by NSAIDs.	Contraindicated
Women in the last (third) trimester of pregnancy.	Contraindicated
Use on broken, damaged, or infected skin.	Prohibited
Children under the minimum regulatory age (typically 12 or 14 years).	Contraindicated/Not Recommended

Populations with Restricted or Conditional Use

Use is not recommended during the first six months of pregnancy and during lactation (breastfeeding). Individuals with a history of peptic ulcers, renal problems, or hypertension/heart failure are advised to seek medical guidance before use, as regulatory labels highlight caution for these comorbidities. Adults and adolescents above the specific minimum age threshold are the only populations approved for standard use.

What should I know about interactions with other medicines?

The interaction profile for Дип Рилиф is primarily structured around the potential systemic risks of its active NSAID component, Ibuprofen. Due to the product’s low topical absorption, official regulatory documents qualify these risks as generally remote under normal conditions, but list them for formal caution.

Interaction Scope

Category	Documented Interacting Substances
Medicinal Products	Anticoagulants, oral corticosteroids, anti-hypertensive agents, lithium, methotrexate, and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Substance	Alcohol (Ethanol).

Official Interaction Statements

Regulatory documents state that co-administration may lead to:

Pharmacodynamic Effects: An enhanced effect of anticoagulants, increasing the risk of bleeding. A concurrent risk of gastrointestinal bleeding or ulceration exists with oral corticosteroids and other antiplatelet agents.
Exposure Modification: A pharmacokinetic interaction is documented with Lithium and Methotrexate, where Ibuprofen may reduce the renal clearance of these drugs, potentially increasing their plasma concentrations.
Restrictions: The official label strictly prohibits the simultaneous use on the same site with any other topical medicine. The concurrent use of other NSAIDs is formally discouraged due to the risk of additive adverse reactions.

Contextual Summary

This interaction structure emphasizes official, label-based constraints, detailing potential pharmacokinetic and pharmacodynamic outcomes that require caution. These documented risks are particularly relevant if the product is used over large areas, for prolonged periods, or in patients with pre-existing renal, hepatic, or cardiac impairment.

Mechanism of Action

Дип Рилиф acts through a dual-mechanism approach via its two active components, ibuprofen and levomenthol.

Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), functions primarily as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This enzymatic inhibition prevents the conversion of arachidonic acid into prostanoids, including prostaglandins and thromboxanes, at the localized site of application. The subsequent reduction in prostaglandin synthesis leads to a modulation of the biochemical cascade responsible for vasodilation and increased vascular permeability in affected tissues.

Levomenthol contributes a distinct mechanistic action. Upon topical application, it interacts directly with the sensory nerve endings in the epidermis, primarily by agonizing the transient receptor potential cation channel subfamily M member 8 (TRPM8) cold receptors. This interaction results in the generation of localized sensory signals within the cutaneous nerve fibers. Furthermore, levomenthol acts as a penetration enhancer, facilitating the transdermal transport of ibuprofen to the underlying tissue and local target sites.

Dosage and Administration Information

The administration of Дип Рилиф is strictly limited to topical application onto the skin surface, as the medicine is formulated as a gel and is for external use only. The instruction is to apply a thin layer, measured as a strip of gel approximately 1 to 4 centimeters in length, directly over the affected area. This measured quantity corresponds to an approximate dose of 50 mg to 125 mg of ibuprofen per application. Following application, the gel should be massaged gently into the skin until it is fully absorbed. Post-application hygiene requires washing the hands immediately, unless the hands themselves are the site of treatment.

The frequency of use is limited to a maximum of three applications per day, ensuring that there is a mandatory minimum interval of four hours between each dose to remain within the established daily limits. Guidelines recommend using the lowest effective amount for the shortest possible duration of treatment. The use of this topical preparation is intended for adults, the elderly, and children over 12 years of age, but it is not recommended for pediatric patients younger than 12.

Specific procedural constraints govern the use of the gel: the treated area must not be covered with occlusive dressings, plasters, or bandages. Furthermore, if the pain or swelling does not resolve or worsens after two weeks of continuous administration, guidelines specify discontinuing use and seeking guidance from a healthcare professional.

Recent Clinical Evidence

Дип Рилиф: Recent Clinical Evidence

Evidence for Use in Acute Soft Tissue Injuries

Research has explored the use of this topical combination gel in conditions characterized by acute or disruptive episodes, such as pain measured in contexts including sprains, strains, and contusions. Studies conducted for this purpose primarily involve short-term Randomized Controlled Trials (RCTs) and comparative-effectiveness studies. These trials were designed to examine how symptoms are measured in adults and adolescents (typically those 16 years of age and older) experiencing acute symptoms following minor trauma. Studies monitored changes in pain intensity scores and the time interval to reach a predefined level of pain reduction.

Findings describe patterns observed in the studies regarding measured changes in physical discomfort during immediate observation periods. The research highlights changes measured when the gel was used for acute symptoms over defined time intervals, such as over the course of approximately one week. Studies also explored the patient-reported experience related to the perceived surface sensation from the Levomenthol component.

Evidence for Use in Localized Musculoskeletal and Rheumatic Pain

Research for chronic or recurring discomfort is primarily extrapolated from systematic reviews and meta-analyses that cover the overall class of topical non-steroidal anti-inflammatory drugs (NSAIDs). These studies were applied in research contexts involving fluctuating or unstable symptoms, such as localized, non-serious arthritic discomfort. Research examined populations of adults with chronic localized pain, often focusing on conditions characterized by functional limitations in a single joint.

Studies monitored outcomes linked to physical discomfort and daily functioning or activity level over intermediate periods, typically ranging from two to four weeks. Findings described patterns observed where the product was compared against a non-active carrier gel, documenting how patient-reported outcomes describing perceived discomfort evolved in the observed populations. Research describes that the differences observed between the active gel and the non-active carrier gel may vary across studies.

Durability of Effect and Long-Term Follow-up Data

Studies conducted during periods of increased symptom activity generally report outcomes that reflect the specific conditions under which they were conducted. For acute injuries, the defined time intervals for observation were typically short (up to seven days). For chronic conditions, follow-up durations were typically limited to between two and four weeks.

Long-term effects are not fully established. There is limited information that characterizes the durability of any measured response when the gel is used for ongoing symptomatic management over many months. The current research provides insight into short-term changes but does not fully explore outcomes related to the maintenance of symptom change or functional measures over extended durations.

What Research Gaps and Uncertainties Remain

Research has explored the use of this topical gel in populations including adults and adolescents. Data for certain groups remain insufficient. Specifically, research does not fully characterize the measured outcomes in very young children or in populations defined by significant comorbidity-defined groups. Similarly, there is limited information available that directly addresses how the gel performs in older adults compared to younger patients.

The most prominent gap is the limited information for long-term outcomes when the specific combination gel is applied across different conditions.
Results apply only to the populations studied, and comparative evidence against other forms of pain relief is sometimes lacking, particularly in long-term follow-up.
The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes, indicating that the research does not determine whether an individual will respond similarly.

Key Studies & References

NICE Guideline: Non-steroidal anti-inflammatory drugs (NSAIDs) for acute pain management (recommendations on topical use).

Frequently Asked Questions (FAQ)

Common questions about Дип Рилиф (FAQ)

Q: How quickly does Дип Рилиф start to work after applying it?

A: Official documents describe that the gel's relief is based on a dual mechanism. One active ingredient, levomenthol, is known to quickly interact with nerve endings on the skin to produce a rapid, noticeable cooling sensation. The second ingredient, ibuprofen, works at a deeper tissue level to address inflammation over time.

Q: Is it normal to feel a warming or cooling sensation after applying Дип Рилиф?

A: Yes, noticing a cooling sensation is a known and expected effect due to the action of the levomenthol component in the gel. Patient Information Leaflets often mention that a tingling or cooling feeling may occur upon application.

Q: Is Дип Рилиф absorbed into the bloodstream?

A: Regulatory documents confirm that the active ingredient, ibuprofen, is known to be absorbed systemically (into the bloodstream) after application to the skin. However, official information describes this systemic absorption as low under normal conditions of use.

Q: Is it safe to apply Дип Рилиф before exercise?

A: Regulatory documents do not specifically mention the use of the gel in relation to exercise. However, the product labels warn that using the product under occlusive conditions, such as tight bandages, or over large areas increases the possibility of systemic side effects.

Q: What is the difference between Дип Рилиф and other similar topical gels?

A: The product is officially characterized as a dual-active component topical preparation. Its distinguishing feature is the combination of two active ingredients: an anti-inflammatory agent (ibuprofen) and a counter-irritant (levomenthol). This combined approach is designed to provide both rapid surface relief and deeper anti-inflammatory action.

Q: What if I accidentally swallow a small amount of Дип Рилиф?

A: The product is for external use only. In the event of accidental ingestion, regulatory documents state that a doctor, the nearest hospital, or a Poison Control Centre should be contacted for guidance.

Q: Can using Дип Рилиф mask a more serious injury?

A: Official guidance includes the instruction to stop using the product and consult a healthcare professional if pain or swelling persists or worsens after the defined treatment period. This ensures the underlying condition can be re-evaluated and is not masked by the pain relief.

Q: Does Дип Рилиф have a strong smell?

A: The smell associated with the product is primarily due to the levomenthol component, which imparts a light menthol fragrance. Official product documentation describes the gel itself as clear and non-greasy.

Q: Can I apply Дип Рилиф under a bandage or heat pack?

A: Regulatory documents explicitly state that the area where the gel is applied should not be covered with occlusive dressings, plasters, or bandages. Additionally, some product labels specifically advise against the simultaneous use of external heat, such as electric heating pads.

Q: Is Дип Рилиф appropriate for use by older adults?

A: The product information states it is approved for use by adults, including the elderly. However, official safety warnings note that the elderly have an increased frequency of adverse reactions to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and the product label highlights caution for those with existing health conditions.

Q: Does Дип Рилиф contain any non-medicinal ingredients I should be aware of?

A: Yes, official regulatory documents list the inactive ingredients, or excipients, used in the gel base. For example, some Patient Information Leaflets note the presence of propylene glycol and mention that this substance may cause skin irritation.

Q: Do any official documents describe potential interactions with herbal supplements?

A: Official regulatory documents detail known interactions with prescription medications, such as anticoagulants and other NSAIDs. The official documents do not typically list specific herbal supplements. Patients are generally advised to consult official resources for all products they are using.

Q: Is it correct that Дип Рилиф contains an ingredient derived from plants?

A: Levomenthol is the ingredient in question. It is derived from or synthesized based on a compound found in mint plants, such as peppermint. This component provides the cooling sensation described in the official product information.

Q: What color is the Дип Рилиф gel?

A: Official regulatory documentation describes the pharmaceutical form of the medicine as a clear and colorless gel.

Q: Can Дип Рилиф be used on the face?

A: Regulatory documents explicitly restrict use on or near mucous membranes or the eyes. This means the gel should not be applied to areas of the face close to these sensitive structures.

Q: Is it normal for the skin to look slightly red after application?

A: Erythema (redness) is listed in regulatory documents as a common skin-related adverse reaction. Some Patient Information Leaflets describe that a slight redness or burning feeling can occur where the gel has been applied, which may not require stopping use unless the reaction worsens or is persistent.

How should Дип Рилиф be stored and disposed of?

How to Store and Dispose of Дип Рилиф

Storage Requirements

Дип Рилиф Gel must be stored out of the sight and reach of children to prevent accidental ingestion. The product requires specific temperature control; it must be kept in a cool place and stored at or below 25, C or 30, C, depending on regional regulatory labeling. To maintain stability, the tube should be kept in the outer carton and the cap must be closed tightly after each use. The gel must not be used after the expiry date printed on the packaging.

Disposal Instructions

For proper disposal, return all unused or expired Дип Рилиф Gel to a pharmacist. It is a mandatory regulatory requirement not to dispose of the unused medicine in drains or sewerage systems.

Дип Рилиф